Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.

Altman JK, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, Frankfurt O, Abaza Y, Bixby DL, Emadi A, Burch M, Bhatnagar B, Luger SM, Percival ME, Wolach O, Craig M, Ganzel C, Roboz G, Levi I, Gourevitch A, Flaishon L, Tessler S, Blumberg C, Gengrinovitch S, Ben Yakar R, Rowe JM

Open source

DOI: 10.1182/bloodadvances.2023010943
Published: 2023 Dec 26
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2023010943,
  title = {Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.},
  author = {Altman JK and Zuckerman T and Koprivnikar J and McCloskey J and Kota V and Keng M and Frankfurt O and Abaza Y and Bixby DL and Emadi A and Burch M and Bhatnagar B and Luger SM and Percival ME and Wolach O and Craig M and Ganzel C and Roboz G and Levi I and Gourevitch A and Flaishon L and Tessler S and Blumberg C and Gengrinovitch S and Ben Yakar R and Rowe JM},
  year = {2023},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2023010943},
  url = {https://doi.org/10.1182/bloodadvances.2023010943}
}

RIS

TY  - JOUR
TI  - Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
AU  - Altman JK
AU  - Zuckerman T
AU  - Koprivnikar J
AU  - McCloskey J
AU  - Kota V
AU  - Keng M
AU  - Frankfurt O
AU  - Abaza Y
AU  - Bixby DL
AU  - Emadi A
AU  - Burch M
AU  - Bhatnagar B
AU  - Luger SM
AU  - Percival ME
AU  - Wolach O
AU  - Craig M
AU  - Ganzel C
AU  - Roboz G
AU  - Levi I
AU  - Gourevitch A
AU  - Flaishon L
AU  - Tessler S
AU  - Blumberg C
AU  - Gengrinovitch S
AU  - Ben Yakar R
AU  - Rowe JM
PY  - 2023
JO  - Blood advances
DO  - 10.1182/bloodadvances.2023010943
UR  - https://doi.org/10.1182/bloodadvances.2023010943
ER  -

APA

JK, A., T, Z., J, K., J, M., V, K., M, K., O, F., Y, A., DL, B., A, E., M, B., B, B., SM, L., ME, P., O, W., M, C., C, G., G, R., I, L., A, G., L, F., S, T., C, B., S, G., R, B. Y., & JM, R. (2023). Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.. Blood advances. https://doi.org/10.1182/bloodadvances.2023010943

Source records

pubmed · retrieved 2026-09-26T19:48:18.251Z